Zoetis: Leading the Pack in Animal Health, but Is It Time to Buy?
📈 Zoetis demonstrates consistent financial growth, with operating profit increasing between 5-10% annually over the last three years and maintaining strong margins around 40%.
💰 The company boasts a 14-year track record of consecutive dividend increases, supported by a reasonable payout ratio of approximately 35%, although the current yield is modest at 1.2%.
⏳ While Zoetis holds a leadership position in an expanding market, its current valuation (P/E near 30) isn't considered a bargain, suggesting potential investors might wait for a pullback towards the lower end of its recent trading range ($145-$190).
Zoetis: A Leader in Animal Health Poised for Growth with Rate Cuts
🐶 Zoetis is a global leader in animal health, with a wide range of products for pets and livestock.
📈 The animal health market is expected to expand by 4-6% annually, reaching $90 billion by 2033.
🔬 The company has 15 medicines generating over $100 million in annual sales each.
💸 Lower interest rates allow Zoetis to invest more in research and development, accelerating innovation.
